Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,20150302,GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),,7.1,13577,DB00047,Insulin Glargine
,20150302,GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),,3.9,13578,DB00047,Insulin Glargine
,20150302,time to reach GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),min,116,13579,DB00047,Insulin Glargine
,20150302,time to reach GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),min,209,13580,DB00047,Insulin Glargine
,25963320,half-life,"Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties compared to insulin glargine (IGlar) including a long half-life of ∼25 h and a duration of action >42 h at steady state, providing a flat and stable blood glucose-lowering effect when injected once daily.",Clinical use of insulin degludec. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963320/),h,∼25,18668,DB00047,Insulin Glargine
>,25963320,duration of action,"Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties compared to insulin glargine (IGlar) including a long half-life of ∼25 h and a duration of action >42 h at steady state, providing a flat and stable blood glucose-lowering effect when injected once daily.",Clinical use of insulin degludec. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963320/),h,42,18669,DB00047,Insulin Glargine
,20357371,maximal glucose infusion rates,"Increases in glucose flux revealed no discernible peak and were modest with maximal glucose infusion rates of 9.4, 6.6, 5.5, and 2.8 mumol/kg/min for the 2.0, 1.5, 1.0, and 0.5 units/kg doses, respectively.",Dose-response effects of insulin glargine in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357371/),[μM] / [kg·min],9.4,62311,DB00047,Insulin Glargine
,20357371,maximal glucose infusion rates,"Increases in glucose flux revealed no discernible peak and were modest with maximal glucose infusion rates of 9.4, 6.6, 5.5, and 2.8 mumol/kg/min for the 2.0, 1.5, 1.0, and 0.5 units/kg doses, respectively.",Dose-response effects of insulin glargine in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357371/),[μM] / [kg·min],6.6,62312,DB00047,Insulin Glargine
,20357371,maximal glucose infusion rates,"Increases in glucose flux revealed no discernible peak and were modest with maximal glucose infusion rates of 9.4, 6.6, 5.5, and 2.8 mumol/kg/min for the 2.0, 1.5, 1.0, and 0.5 units/kg doses, respectively.",Dose-response effects of insulin glargine in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357371/),[μM] / [kg·min],5.5,62313,DB00047,Insulin Glargine
,20357371,maximal glucose infusion rates,"Increases in glucose flux revealed no discernible peak and were modest with maximal glucose infusion rates of 9.4, 6.6, 5.5, and 2.8 mumol/kg/min for the 2.0, 1.5, 1.0, and 0.5 units/kg doses, respectively.",Dose-response effects of insulin glargine in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357371/),[μM] / [kg·min],2.8,62314,DB00047,Insulin Glargine
,25524950,area under the curve (AUC0-24h),"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [24·h·kg],"1,058",83346,DB00047,Insulin Glargine
,25524950,area under the curve (AUC0-24h),"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [24·h·kg],995,83347,DB00047,Insulin Glargine
,25524950,AUC0-12h,"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [12·h·kg],357,83348,DB00047,Insulin Glargine
,25524950,AUC0-12h,"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [12·h·kg],593,83349,DB00047,Insulin Glargine
,25524950,AUC12-24h,"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [24·h·kg],700,83350,DB00047,Insulin Glargine
,25524950,AUC12-24h,"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [24·h·kg],403,83351,DB00047,Insulin Glargine
,25524950,AUC0-24h,"Plasma glucagon levels (AUC0-24h 1,533 ± 656 vs. 1,120 ± 344 ng/L/h, P = 0.027) and lipolysis (free fatty acid AUC0-24h 7.5 ± 1.6 vs.",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[ng] / [h·l],"1,533",83352,DB00047,Insulin Glargine
,25524950,AUC0-24h,"Plasma glucagon levels (AUC0-24h 1,533 ± 656 vs. 1,120 ± 344 ng/L/h, P = 0.027) and lipolysis (free fatty acid AUC0-24h 7.5 ± 1.6 vs.",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[ng] / [h·l],"1,120",83353,DB00047,Insulin Glargine
,25524950,AUC0-24h,"Plasma glucagon levels (AUC0-24h 1,533 ± 656 vs. 1,120 ± 344 ng/L/h, P = 0.027) and lipolysis (free fatty acid AUC0-24h 7.5 ± 1.6 vs.",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),,7.5,83354,DB00047,Insulin Glargine
,25524950,AUC0-24h,"8.9 ± 1.9 mmol/L/h, P = 0.005; β-OH-butyrate AUC0-24h 6.8 ± 4.7 vs. 17.0 ± 11.9 mmol/L/h, P = 0.005; glycerol, P < 0.020) were overall more suppressed after evening versus morning glargine administration.",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mM] / [h·l],6.8,83355,DB00047,Insulin Glargine
,25524950,AUC0-24h,"8.9 ± 1.9 mmol/L/h, P = 0.005; β-OH-butyrate AUC0-24h 6.8 ± 4.7 vs. 17.0 ± 11.9 mmol/L/h, P = 0.005; glycerol, P < 0.020) were overall more suppressed after evening versus morning glargine administration.",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mM] / [h·l],17.0,83356,DB00047,Insulin Glargine
,20508081,G(tot),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg],2512.7,84501,DB00047,Insulin Glargine
,20508081,G(tot),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg],1291.9,84502,DB00047,Insulin Glargine
,20508081,R(max),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg·min],3.740,84503,DB00047,Insulin Glargine
,20508081,R(max),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg·min],1.793,84504,DB00047,Insulin Glargine
,20508081,area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[min·pM] / [l],77 150,84505,DB00047,Insulin Glargine
,20508081,area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[min·pM] / [l],53 111,84506,DB00047,Insulin Glargine
,20508081,maximum serum insulin concentration (C(max)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[pM] / [l],119,84507,DB00047,Insulin Glargine
,20508081,maximum serum insulin concentration (C(max)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[pM] / [l],68,84508,DB00047,Insulin Glargine
,25507175,terminal half-life,"The terminal half-life of IDeg is about 25 hours, which reflects a mean prolongation by factor 2 compared to Insulin glargin (lGlar).",[Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25507175/),h,25,93293,DB00047,Insulin Glargine
,15735188,area under curve above fasting [DeltaAUC] glucose,"As expected, a significant fall in plasma glucose was observed over the exercise period (area under curve above fasting [DeltaAUC] glucose: -0.39 +/- 0.11 vs. -1.30 +/- 0.16 mmol . l(-1) . h(-1); nonexercise vs. exercise; P = 0.001), but insulin levels did not differ significantly on the two occasions (DeltaAUC insulin: -2.1 +/- 3.9 vs.",Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735188/),[mM] / [h·l],-,173639,DB00047,Insulin Glargine
,15735188,area under curve above fasting [DeltaAUC] glucose,"As expected, a significant fall in plasma glucose was observed over the exercise period (area under curve above fasting [DeltaAUC] glucose: -0.39 +/- 0.11 vs. -1.30 +/- 0.16 mmol . l(-1) . h(-1); nonexercise vs. exercise; P = 0.001), but insulin levels did not differ significantly on the two occasions (DeltaAUC insulin: -2.1 +/- 3.9 vs.",Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735188/),[mM] / [h·l],0.39,173640,DB00047,Insulin Glargine
,15735188,area under curve above fasting [DeltaAUC] glucose,"As expected, a significant fall in plasma glucose was observed over the exercise period (area under curve above fasting [DeltaAUC] glucose: -0.39 +/- 0.11 vs. -1.30 +/- 0.16 mmol . l(-1) . h(-1); nonexercise vs. exercise; P = 0.001), but insulin levels did not differ significantly on the two occasions (DeltaAUC insulin: -2.1 +/- 3.9 vs.",Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735188/),[mM] / [h·l],1.30,173641,DB00047,Insulin Glargine
,29709796,time to onset of action,"Median time to onset of action was delayed with glargine compared to detemir (4.0 h [3.3-5.8 h] vs 0.6 h [0.6-1.2 h], P = 0.002).",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,4.0,178947,DB00047,Insulin Glargine
,29709796,time to onset of action,"Median time to onset of action was delayed with glargine compared to detemir (4.0 h [3.3-5.8 h] vs 0.6 h [0.6-1.2 h], P = 0.002).",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,0.6,178948,DB00047,Insulin Glargine
,29709796,time to peak,"There was no difference in time to peak (median [range] = 6.3 h [5.0-21.3 h] vs 4.3 h [2.9-7.4 h], P = 0.15) or duration of action (16.3 h [6.1-20.1 h] vs 10.8 h [8.8-14.8 h], P = 0.21) between glargine and detemir, respectively.",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,6.3,178949,DB00047,Insulin Glargine
,29709796,time to peak,"There was no difference in time to peak (median [range] = 6.3 h [5.0-21.3 h] vs 4.3 h [2.9-7.4 h], P = 0.15) or duration of action (16.3 h [6.1-20.1 h] vs 10.8 h [8.8-14.8 h], P = 0.21) between glargine and detemir, respectively.",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,4.3,178950,DB00047,Insulin Glargine
,29709796,duration of action,"There was no difference in time to peak (median [range] = 6.3 h [5.0-21.3 h] vs 4.3 h [2.9-7.4 h], P = 0.15) or duration of action (16.3 h [6.1-20.1 h] vs 10.8 h [8.8-14.8 h], P = 0.21) between glargine and detemir, respectively.",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,16.3,178951,DB00047,Insulin Glargine
,29709796,duration of action,"There was no difference in time to peak (median [range] = 6.3 h [5.0-21.3 h] vs 4.3 h [2.9-7.4 h], P = 0.15) or duration of action (16.3 h [6.1-20.1 h] vs 10.8 h [8.8-14.8 h], P = 0.21) between glargine and detemir, respectively.",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,10.8,178952,DB00047,Insulin Glargine
,21498786,area under the curve(0-32 h),"The glucose infusion rate area under the curve(0-32 h) was greater for glargine than for detemir and NPH (1,538 ± 688; 1,081 ± 785; and 1,170 ± 703 mg/kg, respectively; P < 0.05).","Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21498786/),[mg] / [kg],"1,538",187655,DB00047,Insulin Glargine
,21498786,area under the curve(0-32 h),"The glucose infusion rate area under the curve(0-32 h) was greater for glargine than for detemir and NPH (1,538 ± 688; 1,081 ± 785; and 1,170 ± 703 mg/kg, respectively; P < 0.05).","Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21498786/),[mg] / [kg],"1,081",187656,DB00047,Insulin Glargine
,21498786,area under the curve(0-32 h),"The glucose infusion rate area under the curve(0-32 h) was greater for glargine than for detemir and NPH (1,538 ± 688; 1,081 ± 785; and 1,170 ± 703 mg/kg, respectively; P < 0.05).","Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21498786/),[mg] / [kg],"1,170",187657,DB00047,Insulin Glargine
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,0.8,189294,DB00047,Insulin Glargine
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,0.5,189295,DB00047,Insulin Glargine
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,1,189296,DB00047,Insulin Glargine
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,1.5,189297,DB00047,Insulin Glargine
,10841002,time,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,3.2,194793,DB00047,Insulin Glargine
,10841002,time,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,8.8,194794,DB00047,Insulin Glargine
,10841002,time,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,11.0,194795,DB00047,Insulin Glargine
,10841002,absorption rate,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,3.2,194796,DB00047,Insulin Glargine
,10841002,absorption rate,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,8.8,194797,DB00047,Insulin Glargine
,10841002,absorption rate,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,11.0,194798,DB00047,Insulin Glargine
,10841002,residual radioactivity,"Mean residual radioactivity with NPH insulin was also significantly lower at 24 h (21.9 vs. 43.8 and 52.2%, P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),%,21.9,194799,DB00047,Insulin Glargine
,10841002,residual radioactivity,"Mean residual radioactivity with NPH insulin was also significantly lower at 24 h (21.9 vs. 43.8 and 52.2%, P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),%,43.8,194800,DB00047,Insulin Glargine
,10841002,residual radioactivity,"Mean residual radioactivity with NPH insulin was also significantly lower at 24 h (21.9 vs. 43.8 and 52.2%, P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),%,52.2,194801,DB00047,Insulin Glargine
,10841002,T75%,"In study 2, there were no significant differences in the absorption characteristics of insulin glargine between the 3 injection sites (T75% = 11.9, 15.3, and 13.2 h for arm, leg, and abdomen, respectively) or in residual radioactivity at 24 h.",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,11.9,194802,DB00047,Insulin Glargine
,10841002,T75%,"In study 2, there were no significant differences in the absorption characteristics of insulin glargine between the 3 injection sites (T75% = 11.9, 15.3, and 13.2 h for arm, leg, and abdomen, respectively) or in residual radioactivity at 24 h.",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,15.3,194803,DB00047,Insulin Glargine
,10841002,T75%,"In study 2, there were no significant differences in the absorption characteristics of insulin glargine between the 3 injection sites (T75% = 11.9, 15.3, and 13.2 h for arm, leg, and abdomen, respectively) or in residual radioactivity at 24 h.",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,13.2,194804,DB00047,Insulin Glargine
,12060061,trough FSI,"Notably, the trough FSI at the end of the sampling periods was almost identical (day 1, 79 +/- 56 pmol/l, day 4, 77 +/- 56 pmol/l, day 11, 86 +/- 60 pmol/l).",No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060061/),[pM] / [l],79,202365,DB00047,Insulin Glargine
,12060061,trough FSI,"Notably, the trough FSI at the end of the sampling periods was almost identical (day 1, 79 +/- 56 pmol/l, day 4, 77 +/- 56 pmol/l, day 11, 86 +/- 60 pmol/l).",No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060061/),[pM] / [l],77,202366,DB00047,Insulin Glargine
,12060061,trough FSI,"Notably, the trough FSI at the end of the sampling periods was almost identical (day 1, 79 +/- 56 pmol/l, day 4, 77 +/- 56 pmol/l, day 11, 86 +/- 60 pmol/l).",No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060061/),[pM] / [l],86,202367,DB00047,Insulin Glargine
,29453671,AUC0-24 h,The geometric LSM AUC0-24 h value for Glaritus® (1.09 h nmol/L) was comparable to Lantus (1.05 h nmol/L).,"Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453671/),[h·nM] / [l],1.09,212363,DB00047,Insulin Glargine
,29453671,AUC0-24 h,The geometric LSM AUC0-24 h value for Glaritus® (1.09 h nmol/L) was comparable to Lantus (1.05 h nmol/L).,"Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453671/),[h·nM] / [l],1.05,212364,DB00047,Insulin Glargine
,29453671,Tmax,"Median Tmax values were also identical (12 h for both), and median t1/2 values were also equal (18 h for both).","Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453671/),h,12,212365,DB00047,Insulin Glargine
,29453671,t1/2,"Median Tmax values were also identical (12 h for both), and median t1/2 values were also equal (18 h for both).","Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453671/),h,18,212366,DB00047,Insulin Glargine
>,19761358,duration of insulin action (tR(last)),The duration of insulin action (tR(last)) for ILPS at 0.8 U/kg was >23 hours and was similar to G (p = 0.114) and D (p = 0.570).,Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761358/),h,23,214521,DB00047,Insulin Glargine
,18471141,time to first nadir glucose,Mean time to first nadir glucose was longer for glargine (14 h) relative to PZI (4 h) and lente (5 h).,Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471141/),h,14,215799,DB00047,Insulin Glargine
,18471141,time to first nadir glucose,Mean time to first nadir glucose was longer for glargine (14 h) relative to PZI (4 h) and lente (5 h).,Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471141/),h,4,215800,DB00047,Insulin Glargine
,18471141,time to first nadir glucose,Mean time to first nadir glucose was longer for glargine (14 h) relative to PZI (4 h) and lente (5 h).,Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471141/),h,5,215801,DB00047,Insulin Glargine
,32719315,Elimination plasma half-life,"Elimination plasma half-life of ~20 h in dogs and ~70 h in man is achieved by a strong albumin binding, and by lowering the insulin receptor affinity 500-fold to slow down receptor mediated clearance.",Molecular engineering of safe and efficacious oral basal insulin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32719315/),h,20,227214,DB00047,Insulin Glargine
,32719315,Elimination plasma half-life,"Elimination plasma half-life of ~20 h in dogs and ~70 h in man is achieved by a strong albumin binding, and by lowering the insulin receptor affinity 500-fold to slow down receptor mediated clearance.",Molecular engineering of safe and efficacious oral basal insulin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32719315/),h,70,227215,DB00047,Insulin Glargine
,17623819,area under the curve [AUC](0-end of GIR)),"Estimated total insulin activity (GIR area under the curve [AUC](0-end of GIR)) was 1,412 +/- 662 and 915 +/- 225 mg/kg (glargine vs. detemir, P < 0.05), with median time of end of action at 24 and 17.5 h (glargine vs. detemir, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),[mg] / [kg],"1,412",236079,DB00047,Insulin Glargine
,17623819,area under the curve [AUC](0-end of GIR)),"Estimated total insulin activity (GIR area under the curve [AUC](0-end of GIR)) was 1,412 +/- 662 and 915 +/- 225 mg/kg (glargine vs. detemir, P < 0.05), with median time of end of action at 24 and 17.5 h (glargine vs. detemir, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),[mg] / [kg],915,236080,DB00047,Insulin Glargine
,17623819,time of end of action,"Estimated total insulin activity (GIR area under the curve [AUC](0-end of GIR)) was 1,412 +/- 662 and 915 +/- 225 mg/kg (glargine vs. detemir, P < 0.05), with median time of end of action at 24 and 17.5 h (glargine vs. detemir, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),h,24,236081,DB00047,Insulin Glargine
,17623819,time of end of action,"Estimated total insulin activity (GIR area under the curve [AUC](0-end of GIR)) was 1,412 +/- 662 and 915 +/- 225 mg/kg (glargine vs. detemir, P < 0.05), with median time of end of action at 24 and 17.5 h (glargine vs. detemir, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),h,17.5,236082,DB00047,Insulin Glargine
,17623819,AUC free fatty acids(0-24 h),"The antilipolytic action of detemir was lower than that of glargine (AUC free fatty acids(0-24 h) 11 +/- 1.7 vs. 8 +/- 2.8 mmol/l, respectively, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),[mM] / [l],11,236083,DB00047,Insulin Glargine
,17623819,AUC free fatty acids(0-24 h),"The antilipolytic action of detemir was lower than that of glargine (AUC free fatty acids(0-24 h) 11 +/- 1.7 vs. 8 +/- 2.8 mmol/l, respectively, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),[mM] / [l],8,236084,DB00047,Insulin Glargine
,31407113,absolute bioavailability,Approximately 6% absolute bioavailability in the bloodstream was estimated for the same formulation through in vivo pharmacokinetic studies in rats.,Lipid nanoparticles as vehicles for oral delivery of insulin and insulin analogs: preliminary ex vivo and in vivo studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31407113/),%,6,242840,DB00047,Insulin Glargine
>,31280022,duration of action,"The duration of action of IDeg in people is > 42 h, allowing flexibility in daily administration.",Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31280022/),h,42,244397,DB00047,Insulin Glargine
,31280022,time to peak action (TPEAK),"On average, time to peak action (TPEAK) of IGla-U300 was 145 ± 114 min (95% confidence interval [CI] = 25-264) longer than TPEAK of IDeg (P = 0.03) and duration of action (TDUR) of IGla-U300 was 250 ± 173 min (95% CI = 68-432) longer than TDUR of IDeg (P = 0.02).",Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31280022/),min,145,244398,DB00047,Insulin Glargine
,31280022,duration of action (TDUR),"On average, time to peak action (TPEAK) of IGla-U300 was 145 ± 114 min (95% confidence interval [CI] = 25-264) longer than TPEAK of IDeg (P = 0.03) and duration of action (TDUR) of IGla-U300 was 250 ± 173 min (95% CI = 68-432) longer than TDUR of IDeg (P = 0.02).",Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31280022/),min,250,244399,DB00047,Insulin Glargine
,24139704,peak,"Following injection of insulin detemir, GIR increased, reaching a mean peak of 2.29 mg/kg/min (95% CI 1.64, 2.94) at 11.6h (range 8.9 to 14.3) compared to 1.71 mg/kg/min (95% CI 1.4, 2.0) at 10.2 h (8.1 to 12.3) for insulin glargine (P=0.025 for GIR(max)).",A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24139704/),[mg] / [kg·min],2.29,265150,DB00047,Insulin Glargine
,24139704,peak,"Following injection of insulin detemir, GIR increased, reaching a mean peak of 2.29 mg/kg/min (95% CI 1.64, 2.94) at 11.6h (range 8.9 to 14.3) compared to 1.71 mg/kg/min (95% CI 1.4, 2.0) at 10.2 h (8.1 to 12.3) for insulin glargine (P=0.025 for GIR(max)).",A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24139704/),[mg] / [kg·min],1.71,265151,DB00047,Insulin Glargine
,26086190,half-life,"At SS, the half-life was 25.4 (IDeg) versus 12.1 h (IGlar).",Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26086190/),h,25.4,265556,DB00047,Insulin Glargine
,26086190,half-life,"At SS, the half-life was 25.4 (IDeg) versus 12.1 h (IGlar).",Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26086190/),h,12.1,265557,DB00047,Insulin Glargine
>,26086190,half-life,IDeg has a longer half-life (> 25 h) than IGlar.,Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26086190/),h,25,265558,DB00047,Insulin Glargine
,24504686,Time-to-maximum plasma concentration,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,18.0 to 42.0,271201,DB00047,Insulin Glargine
,24504686,Time-to-maximum plasma concentration,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,10.0-12.0,271202,DB00047,Insulin Glargine
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,18.0 to 42.0,271203,DB00047,Insulin Glargine
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,24.4-45.5,271204,DB00047,Insulin Glargine
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,10.0-12.0,271205,DB00047,Insulin Glargine
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,12.2-14.9,271206,DB00047,Insulin Glargine
,24504686,apparent clearance,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,24.4-45.5,271207,DB00047,Insulin Glargine
,24504686,apparent clearance,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),[l] / [h],1.8-2.8,271208,DB00047,Insulin Glargine
,24504686,apparent clearance,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,10.0-12.0,271209,DB00047,Insulin Glargine
,24504686,t½,"After IV administration, LY2605541's geometric mean t½ was 2.3 hours.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,2.3,271210,DB00047,Insulin Glargine
